Endothelial dysfunction is involved in the process of acute myocardial infarction (AMI), that is, the endothelial cell–specific molecule 1 (ESM-1; endocan) is a novel endothelial dysfunction marker. However, the relationship between patients with AMI and serum ESM-1 levels is not very clear. Patients with AMI (n = 216) and a control group (n = 60) without AMI were included in the study. High-sensitivity C-reactive protein (hsCRP) was measured, and the severity of AMI was assessed by a modified Gensini stenosis scoring system. Serum ESM-1 levels were significantly higher in the AMI group (P < .05). High-sensitivity C-reactive protein levels were also significantly higher in the AMI group (P < .05). In patients with AMI, serum ESM-1 levels were not significantly correlated with hsCRP levels. There was no significant correlation between serum ESM-1 level and Gensini score. Our findings suggest that serum ESM-1 levels may be a novel biomarker of endothelial dysfunction in patients with AMI.
GoASMozaffarianDRogerVL; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics—2014 update: a report from the American Heart Association. Circulation. 2014;129(3):e28–e292.
2.
RadeckeCEWarrickAESinghGDRogersJHSimonSI1ArmstrongEJ. Coronary artery endothelial cells and microparticles increase expression of VCAM-1 in myocardial infarction. Thromb Haemost. 2015;113(3):605–616.
PedersenFButrymovichVKelbækH. Short- and long-term cause of death in patients treated with primary PCI for STEMI. J Am Coll Cardiol. 2014;64(20):2101–2108.
6.
BaltaSDemirkolSCelikT. Association between coronary artery ectasia and neutrophil-lymphocyte ratio. Angiology. 2013;64(8):627–632.
7.
BaltaSMikhailidisDPDemirkolS. Endocan—a novel inflammatory indicator in newly diagnosed patients with hypertension: a pilot study. Angiology. 2014;65(9):773–777.
8.
MenonPKocherONAirdWC. Endothelial cell specific molecule-1 (ESM-1), a novel secreted proteoglycan stimulates vascular smooth muscle cell proliferation and migration. Circulation. 2011;124(21):a15455.
9.
KoseMEmetSAkpinarTS. Serum Endocan Level and the Severity of Coronary Artery Disease: A Pilot Study. Angiology. 2015;66(8):727–731.
10.
ThygesenKAlpertJSJaffeAS. Third universal definition of myocardial infarction. J Am Coll Cardiol. 2012; 60(16):1581–1598.
11.
GensiniGG. A more meaningful scoring system for determining the severity of coronary heart disease. Am J Cardiol. 1983,51(3):606.
12.
LassallePMoletSJaninA. ESM-1 is a novel human endothelial cell-specific molecule expressed in lung and regulated by cytokines. J Biol Chem. 1996;271(34):20458–20464.
13.
BéchardDGentinaTDeleheddeM. Endocan is a novel chondroitin sulfate/dermatan sulfate proteoglycan that promotes hepatocyte growth factor/scatter factor mitogenic activity. J Biol Chem. 2001;276(51):48341–48349.
14.
FrahmKANashCPTobetSA. Endocan immunoreactivity in the mouse brain: method for identifying nonfunctional blood vessels. J Immunol Methods. 2013;398-399:27–32.
15.
CarrilloLMArciniegasERojasHRamírezR. Immunolocalization of endocan during the endothelial-mesenchymal transition process. Eur J Histochem. 2011;55(2):e13.
16.
BéchardDScherpereelAHammadH. Human endothelial-cell specific molecule-1 binds directly to the integrin CD11a/CD18 (LFA-1) and blocks binding to intercellular adhesion molecule-1. J Immunol. 2001;167(6):3099–3106.
17.
BaltaIBaltaSKoryurekOM. Serum endocan levels as a marker of disease activity in patients with Behçet disease. J Am Acad Dermatol. 2014;70(2):291–296.
18.
YangJYangQYuSZhangX. Endocan: a new marker for cancer and a target for cancer therapy. Biomed Rep. 2015;3(3):279–283.
19.
RochaSFSchillerMJingD. ESM1 modulates endothelial tip cell behavior and vascular permeability by enhancing VEGF bioavailability. Circ Res. 2014;115(6):581–590.
20.
MikkelsenMEShahCVScherpereelA. Lower serum endocan levels are associated with the development of acute lung injury after major trauma. J Crit Care. 2012;27(5):522.e11–e17.
21.
HatfieldKJLassallePLeivaRALindåsRWendelboeØBruserudØ. Serum levels of endothelium-derived endocan are increased in patients with untreated acute myeloid leukemia. Hematology. 2011;16(6):351–356.
22.
LvZFanYChenHZhaoD. Endothelial cell-specific molecule-1: a potential serum marker for gastric cancer. Tumour Biol. 2014;35(10):10497–10502.
23.
OzakiKToshikuniNGeorgeJ. Serum endocan as a novel prognostic biomarker in patients with hepatocellular carcinoma. J Cancer. 2014;5(3):221–230.
24.
MihajlovicDMLendakDFBrkicSV. Endocan is useful biomarker of survival and severity in sepsis. Microvasc Res. 2014;93:92–97.
25.
LeroyXAubertSZiniL. Vascular endocan (ESM-1) is markedly overexpressed in clear cell renal cell carcinoma. Histopathology. 2010;56(2):180–187.
26.
BaltaSMikhailidisDPDemirkolSOzturkCCelikTIyisoyA. Endocan: a novel inflammatory indicator in cardiovascular disease?Atherosclerosis. 2015;243(1):339–343.
27.
NiralaBKPerumalVGohilNK. Glycated serum albumin stimulates expression of endothelial cell specific molecule-1 in human umbilical vein endothelial cells: Implication in diabetes mediated endothelial dysfunction. Diab Vasc Dis Res. 2015;12(4):290–297.
28.
AparciMIsilakZUzOYalcinMKucukU. Endocan and endothelial dysfunction. Angiology. 2015;66(5):488–489.
29.
BaltaSMikhailidisDPDemirkolSCelikTOzturkCIyisoyA. Endocan and atherosclerosis. Angiology. 2015;66(5):490.
30.
BaltaSOzturkC. Endocan, Obstructive Sleep Apnea, and Vascular Risk. Angiology. 2016;67(4):305–306.
31.
YilmazMISiriopolDSaglamM. Plasma endocan levels associate with inflammation, vascular abnormalities, cardiovascular events, and survivalin chronic kidney disease. Kidney Int. 2014;86(6):1213–1220.
32.
WangXSYangWLuoTWangJMJingYY. Serum endocan levels are correlated with the presence and severity of coronary artery disease in patients with hypertension. Genet Test Mol Biomarkers. 2015;19(3):124–127.
33.
QiuCSuiJZhangQWeiPWangPFuQ. Relationship of Endothelial Cell-Specific Molecule 1 Level in Stress Hyperglycemia Patients With Acute ST-Segment Elevation Myocardial Infarction: A Pilot Study. Angiology. 2016;67(9):829–834.
34.
CoxLAvan EijkLTRamakersBP. Inflammation-induced increases in plasma endocan levels are associated with endothelial dysfunction in humans in vivo. Shock. 2015;43(4):322–326.
35.
BlausAMadabushiRPacanowskiM. Personalized Cardiovascular Medicine Today: A Food and Drug Administration/Center for Drug Evaluation and Research Perspective. Circulation. 2015;132(15):1425–1432.
36.
TadzicRMihaljMVcevAEnnenJTadzicADrenjancevicI. The effects of arterial blood pressure reduction on endocan and soluble endothelial cell adhesion molecules (CAMs) and CAMs ligands expression in hypertensive patients on Ca-channel blocker therapy. Kidney Blood Press Res. 2013;37(2-3):103–115.
